

DAFTAR PUSTAKA

- Ahmed A., Ryan B. P., Stephen A. H. High Prevalence of Hepatic Fibrosis in the Setting of Coexisting Diabetes and Hepatic Steatosis: A Case for Selective Screening in the General Population?. *Hepatology*, 2016, 63(1): 20-22.
- Akramiene D., Kondrotas A., Didziapetriene J., Kevelaitis E. Effects of beta-glucans on the immune system. *Medicina*, 2007, 43(8): 597-606.
- Altamirano J., Javier M. Alcohol Consumption as a Cofactor for Other Liver Diseases. *Clinical Liver Disease*, 2013, 2(2): 72-75.
- Anshori M dan Sri Iswati. 2009 . *Buku Ajar Metodologi Penelitian Kuantitatif*, Airlangga University Press, Surabaya.
- Barclay A. W., Petocz P., McMillan-Price J., Flood V. M., Prvan T., et al. Glycaemic index, glycaemic load, and chronic disease risk – a meta-analysis of observational studies. *American Journal of Clinical Nutrition*, 2008, 87(3): 627-637
- Bataller R., David A.B. Liver Fibrosis. *The Journal of Clinical Investigation*, 2005, 115(2): 209-218.
- Benhamou Y., Marie B., Vincent D. M., Frederic C., Felipe A., Anne C., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. *Hepatology*, 1999, 30(4): 1054-1058.
- Blachier M., Henri L., Markus P. R., Dominique C. V., Francoise R. T. The Burden of Liver Disease in Europe: A Review of Available Epidemiological Data. *Journal of Hepatology*, 2013, 58(3): 593-608.
- Brenner D. A. Molecular Pathogenesis of Liver Fibrosis. *Transactions of the American Clinical and Climatological Association*, 2009, 120: 361-368.
- Chiang D.J., Pritchard M.T., Nagy L.E. Obesity, diabetes mellitus, and liver fibrosis. *American Journal of Physiology, Gastrointestinal and Liver Physiology*, 2011, 300(5): G697-702.
- Corpechot C., Farid G., Yves C., Catherine J., Oliver C., Raoul P. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. *Journal of Hepatology*, 2012, 56(1): 218-224.
- Cramer D., Wagner, Stephanie, Li, Bing et al. 2008. *Mobilization of Hematopoietic Progenitor Cells by Yeast-Derived Beta-Glucan Requires Activation of Matrix Metalloproteinase-9*. NCBI.

Domitrović R., Hrvoje J., Jelena T., Ivana Š. Liver Fibrosis in Mice Induced by Carbontetrachloride and Its Reversion by Luteolin. *Toxicology and Applied Pharmacology*, 2009, 24(1): 311–321.

Elgert K. D. 2009. *Immunology: Understanding The Immune System*. Blackwell Scientific Publication, United States of America.

European Food Safety Authority (EFSA). *Scientific Opinion on the safety of 'yeast beta-glucans' as a Novel Food Ingredient*. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). *EFSA Journal*, 2011, 9(5):2137.

Fan X, Zhang Q, Li S, Lv Y, Su H, et al. Attenuation of CCl₄-Induced Hepatic Fibrosis in Mice by Vaccinating against TGF- β 1. *PLoS ONE*, 2013, 8(12): e82190.

Fausto N., Campbell J.S., Riehle K.J. Liver regeneration. *Hepatology*, 2006, 43: S45–S53.

Fitria Nur L., Diana L., Mudjiwijono H. Efek Pemberian Asam Alfa Lipoat terhadap Kadar MDA dan Gambaran Histologi pada Hati Tikus Wistar Jantan dengan Diabetes Melitus Tipe 1. *Jurnal Kedokteran Brawijaya*, 2015, 28(3): 170-176.

Franzke A. The role of G-CSF in adaptive immunity. *Cytokine Growth Factor*, 2006, 17: 235–44.

Fujii T, Fuch BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al., Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. *BMC Gastroenterol*, 2010, 10: 79.

Hernandez-Gea V. dan Friedman SL. Pathogenesis of Liver Fibrosis. *Annual Review of Pathology*, 2011, 6: 425-456.

Hunter K. W., R.A Gault, M.D. Berner. Preparation of microparticulate β -glucan from *Saccharomyces cerevisiae* for use in immune potentiation. *Letters in Applied Microbiology*, 2002, 35(4): 267-71.

Iredale, JP. Hepatic Stellate Cells Behavior during Resolution of Liver Injury. *Europe PubMed Central*, 2001, 21(3): 427-436. doi: 10.1055/s-2001-17557

Ismail MH dan Massimo P. Reversal of Liver Fibrosis. *Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association*, 2009, 15(1): 72-79. doi 10.4103/1319-3767.45072.

Ito K, Masuda Y, Yamasaki Y, Yokota Y, Nanba H. Maitake beta-Glucan Enhances Granulopoiesis and Mobilization of Granulocytes by Increasing G-CSF Production and Modulating CXCR4/SDF-1 Expression. *Kobe: International Immunopharmacology*, 2009, 9(10): 1189–1196.

- Jaeschke H. dan Anup R.. Reactive Oxygen Species in the Normal and Acutely Injured Liver. *Journal of Hepatology*, 2011, 55(1): 227-228. doi: 10.1016/j.jhep.2011.01.006
- Kallis Y. N., M. R. Alison, S. J. Forbes. Bone Marrow Stem Cells and Liver Disease, *Gut*, 2007, 56: 716 – 724.
- Kumar V., Abbas A. K., Aster J. C. 2013. *Robbins Basic Pathology*, 9th Ed, Elsevier, Canada.
- Lee JN, Lee DY, Ji IH, Kim GE, Kim HN, Sohn J, *et al*. Purification of soluble beta-glucan with immune-enhancing activity from the cell wall of yeast. *Bioscience, Biotechnology, and Biochemistry*, 2001, 65(4):837-841.
- Lim Young-Suk dan Kim W. R.. The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease. *Clin Liver Dis*, 2008, 12(4): 733-746.
- Malhi H., Maria E.G., Georgy J. G.. Hepatocyte Death: A Clear and Present Danger. *Physiol Rev*, 2010, 90(3): 1165 – 1194.
- Marie Ng., Tom F., Margaret R., Blake T., Nicholas G., *et al*. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*, 2014, 384(9945): 766-781.
- Mason R.. 2004. *What is Beta glucan A Concise Guide to the Benefits and Uses of the Most Powerful Natural Immune Enhancer Known to Science*. 561 Shunpike, USA.
- MEROPS. 2016. The Peptidase Database. *Saccharomyces cerevisiae*, (Online) (<http://merops.sanger.ac.uk/cgi-bin/speccards?sp=sp000895;type=peptidase>, diakses 15 Januari 2015)
- Paula P., Margaret C.S. 2014. Evaluation and Staging of Liver Fibrosis. *Hepatitis C Online*, (Online) (<http://www.hepatitisc.uw.edu/go/evaluation-staging-monitoring/evaluation-staging/core-concept/all>, diakses 3 Januari 2015)
- Pelizon A.C., R. Kaneno, A.M.V.C. Soares, D.A. Meira, A. Sartori. Immunomodulatory Activities Associated with β -Glucan Derived from *Saccharomyces cerevisiae*. *Physiological Research*, 2005, 54: 557-564.
- Poli G. Pathogenesis of Liver Fibrosis: Role of Oxidative Stress. *Molecular Aspect of Medicine*, 2000, 21(3): 49-98. doi:10.1016/S0098-2997(00)00004-2.
- Poynard T., Pascal L., Patrick I., Anne V., Brigitte V., Yen Ngo, *et al*. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). *Biomed Central Gastroenterology*, 2010, 10(4).
- Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease. *Clinics in Liver Disease*, 2008, 12(4):939-962,xi.

- Sandvik A., Wang Y.Y., Morton H.C., Aasen A.O., Wang J.E., Johansen F.E. Oral and systemic administration of β -glucan protects against lipopolysaccharide-induced shock and organ injury in rats. *Clin Exp Immunol*, 2007, 148(1): 168 – 177. doi:10.1111/j.1365-2249.2006.03320.x.
- Schiavon L. de L., Janaina L. N. Roberto J. de C. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. *World Journal of Gastroenterology*, 2014, 20(11): 2854-2866.
- Schuppan D., Yong O. K. Evolving therapies for liver fibrosis. *The Journal of Clinical Investigation*, 2013, 123(5): 1887-1901.
- Starkel, P. dan Leclercq, I.A. Animal Models for The Study of Hepatic Fibrosis. *Best Practice & Research Clinical Gastroenterology*, 2011, 25: 319-333.
- Taylor P. R., Gordon D. B., Delyth M. R., Janet A. W., Luisa Martinez-Pomarez, et al. The β -glucan Receptor, Dectin-1, Is Predominantly Expressed on the Surface of Cells of the Monocyte/Macrophage and Neutrophil Lineages. *The Journal of Immunology*, 2002, 169(7): 3876 – 3882.
- Tsolaki E. Athanasiou E., Gounari E., Zogas N., Siotou E., Yiangou M., et al. 2014. Hematopoietic stem cells and liver regeneration: Differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury. *Blood Cells, Molecules and Diseases*, 2014, 53: 124–132.
- Utomo Y, A Hidayat, M Dafip, FA Sasi. Studi Histopatologi Hati Mencit (*Mus musculus* L.) yang Diinduksi Pemanis Buatan. *Jurnal MIPA*, 2012, 35(2): 122-129.